Upgrades and Downgrades for Monday 3/19

Upgrades

  • Unilever (UN) upgraded by Goldman Sach from Sell to Neutral
  • Compania Cervecerias (CCU) upgraded by Goldman Sachs from Neutral to Buy
  • AstraZeneca (AZH) upgraded by Jefferies from Hold to Buy
  • Spirit AeroSystems (SPR) upgraded by Vertical Research from Hold to Buy
  • Amdocs (DOX) upgraded by Jefferies from Hold to Buy
  • CGG SA (CGG) upgraded by Societe Generale from Hold to Buy
  • Grainger (GWW) upgraded by Goldman Sachs from Sell to Neutral
  • GGP (GGP) upgraded by Mizuho from Neutral to Buy
  • National CineMedia (NCMI) upgraded by B. Riley FBR from Neutral to Buy
  • Camden Property (CPT) upgraded by UBS from Sell to Neutral
  • Equity Residential (EQR) upgraded by UBS from Neutral to Buy
  • WPP (WPP) upgraded by Pivotal Research from Hold to Buy
  • Sellas Life Sciences (SLS) upgraded by Maxim from Hold to Buy
  • Oshkosh (OSK) upgraded by Deutsche Bank from Hold to Buy
  • Cummins (CMI) upgraded by Deutsche Bank from Sell to Hold
  • HarborOne Bancorp (HONE) upgraded by Sandler O’Neill from Hold to Buy

Downgrades

  • Pernod Ricard (PDRDY) downgraded by Goldman Sachs from Buy to Neutral
  • Latam Airlines (LTM) downgraded by JPMorgan from Neutral to Underweight
  • Scor (SCRYY) downgraded by JPMorgan from Overweight to Neutral
  • GrubHub (GRUB) downgraded by Stifel from Buy to Hold
  • Acushnet Holdings (GOLF) downgraded by Compass Point from Buy to Neutral
  • ASML (ASML) downgraded by Santander from Buy to Hold
  • BlackLine (BL) downgraded by SunTrust from Buy to Hold
  • BRF S.A. (BRFS) downgraded by UBS from Buy to Neutral
  • TC PipeLines (TCP) downgraded by UBS from Buy to Neutral
  • UDR, Inc. (UDR) downgraded by UBS from Buy to Neutral
  • Mersana Therapeutics (MRSN) downgraded by JPMorgan from Overweight to Neutral
  • Novavax (NVAX) downgraded by JPMorgan from Neutral to Underweight
  • Ophthotech (OPHT) downgraded by JPMorgan from Neutral to Underweight
  • Otonomy (OTIC) downgraded by JPMorgan from Neutral to Underweight
  • Arbutus Biopharma (ABUS) downgraded by Wedbush from Outperform to Neutral

fly360Upgrades & Downgrades provided by The Fly at http://www.thefly.com.  The Fly is a leading digital publisher of real-time financial news. Our financial market experts understand that news impacting stock prices can originate from anywhere, at any time. The Fly team scours all sources of company news, from mainstream to cutting-edge, then filters out the noise to deliver short-form stories consisting of only market moving content. Become an informed investor. Try all of TheFly’s services FREE for 14 days by clicking here.